Tabloid

Tabloid Therapeutics is a biotechnology company focused on developing a new class of precision medicines for the treatment of cancer. The company utilizes its proprietary Targeted Ablation of Intracellular Drivers (TABLOID) platform to identify and degrade disease-causing proteins that have historically been considered undruggable. By leveraging advanced protein degradation technologies, Tabloid Therapeutics aims to create highly selective therapies that minimize off-target effects while maximizing therapeutic efficacy. The company's pipeline is currently in the pre-clinical stage, with a primary focus on solid tumors and hematological malignancies.